Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis

Area of Science:

• Oncology
• Cancer Metastasis
• Extracellular Matrix Biology

Background:

• Secondary metastatic cancer is the primary cause of death in solid tumors, with breast cancer metastasis leading to 100% of fatalities.
• Current treatments lack cures for metastatic cancer, highlighting an urgent need for novel therapeutic strategies.
• Lysyl oxidase (LOX) is an extracellular matrix-modifying enzyme implicated in cancer progression.

Purpose of the Study:

• To investigate the role of hypoxic induction of lysyl oxidase (LOX) in breast cancer metastasis.
• To evaluate LOX as a potential therapeutic target for preventing metastatic spread and osteolytic lesions.
• To validate preclinical findings on targeting LOX for therapeutic intervention in metastatic breast cancer.

Main Methods:

• Correlation analysis of hypoxic LOX induction with bone metastasis in estrogen receptor-negative breast cancer models.
• Assessment of LOX inhibition and its downstream effects on premetastatic niche formation.
• Evaluation of metastatic burden in preclinical models of breast cancer metastasis.

Main Results:

• Hypoxic induction of LOX correlates with metastatic dissemination to bone and is crucial for premetastatic osteolytic lesion formation.
• Targeting LOX or its downstream pathways significantly inhibited premetastatic niche formation in breast cancer metastasis models.
• Reduced metastatic burden was observed following LOX inhibition, validating its role in cancer progression.

Conclusions:

• Lysyl oxidase (LOX) is a critical mediator of breast cancer metastasis and osteolytic lesion development.
• Targeting LOX presents a promising therapeutic strategy for preventing cancer metastasis and reducing disease burden.
• Further development of therapeutics targeting LOX is warranted for broad application in solid tumor types.